Skip to main content
. 2016 Apr 14;2016(4):CD004161. doi: 10.1002/14651858.CD004161.pub2
Adverse events: 1. Continuous outcomes (skew)
Study Intervention Mean SD N
Change in BMI ‐ short term (skew)
Covell 2012 Risperidone depot 1.29 1.9 23
Covell 2012 Typical depot antipsychotics 0.48 1.4 26
Change in BMI ‐ medium term (skew)
Covell 2012 Risperidone depot 1.53 2.2 22
Covell 2012 Typical depot antipsychotics 0.53 1.3 24
Change in BMI ‐ long term (skew)
Covell 2012 Risperidone depot 1.04 2.0 17
Covell 2012 Typical depot antipsychotics ‐0.28 1.7 24
Prolactin endpoint levels (ng/mL) ‐ short term (skew)
Covell 2012 Risperidone depot 22.5 19.1 19
Covell 2012 Typical depot antipsychotics 15.1 7.6 22
Prolactin endpoint levels (ng/mL) ‐ medium term (skew)
Covell 2012 Risperidone depot 23.4 13.8 18
Covell 2012 Typical depot antipsychotics 16 7.5 21
Prolactin endpoint levels (ng/mL) ‐ long term (skew)
Covell 2012 Risperidone depot 19 10.6 14
Covell 2012 Typical depot antipsychotics 15.2 5.1 18